A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic Patients

A three-arm, multi-site clinical evaluation of the ARIES Bordetella Assay for the detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acids in prospectively collected, de-identified, left-over clinical specimens; banked, pre-selected clinical specimens; and contrived specimens.

Study Overview

• Status: Completed
• Conditions: Bordetella Infections; Bordetella Pertussis Infection; Bordetella Parapertussis Infection
• Intervention / Treatment: Device: ARIES Bordetella Assay

Detailed Description

The ARIES Bordetella Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acid in nasopharyngeal swabs (NPS) specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis.

Clinical nasopharyngeal swab specimens collected using nasopharyngeal swab in transport media will be processed according to the routine procedure followed at the clinical collection site and as ordered by the referring physician. The leftover specimen will be blinded and assigned a unique clinical study specimen number. In order to preserve the confidentiality of subjects, the following procedures will be implemented at each site:

• Clinical specimens will be individually numbered by an honest broker who is not involved in investigational testing so that the identity of the subject may not be readily ascertained by the investigator, investigational testing staff, or study Sponsor.
• Available clinical information accompanying the specimens will be provided in such a way that it does not make the specimen source identifiable to the investigator or any other individuals associated with investigational testing, including the Sponsor.
• No personal identifier (protected health information) will be included on the case report form (CRF) so that the confidentiality of each subject is protected.

Multiple aliquots of each left-over specimen will be generated. One aliquot of each specimen will be shipped to a laboratory where the reference method (two validated real-time PCR methods for each, B. pertussis and B. parapertussis) will be performed. A second aliquot of each specimen will be used by the clinical sites for ARIES Bordetella Assay testing. Additional aliquots of each specimen will be stored frozen (-65 to -95°C) at the clinical sites and sent separately on dry ice to the Sponsor upon Sponsor's request.

The prospective data set will be supplemented with banked, pre-selected clinical specimens and contrived specimens that tested positive by a comparator method for B. pertussis and B. parapertussis. If contrived specimens are required, these specimens will be prepared then blinded, aliquoted, randomized and frozen (-65 to -95°C) until distributed to the clinical testing sites by the Sponsor.

The clinical data will be automatically generated from the ARIES System software. The system will report the specimen as B. pertussis and B. parapertussis positive (Co-infection), B. pertussis positive, B. parapertussis positive, B. pertussis and B. parapertussis negative or Invalid. Invalid results will be retested and both the original data and the retest data will be reported. The clinical data will be compared to the reference data and recorded in the clinical study reports.

• Study Type: Interventional
• Enrollment (Actual): 1052
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 1Y8
      • Luminex Molecular Diagnostics
• United States
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Indiana University Health
  • Michigan
    • Grosse Pointe Woods, Michigan, United States, 48230
      • St. John Hospital and Medical Center
  • New Mexico
    • Albuquerque, New Mexico, United States, 87102
      • TriCore
  • Ohio
    • Columbus, Ohio, United States, 43205
      • Nationwide Children's Hospital Laboratory
  • Wisconsin
    • Marshfield, Wisconsin, United States, 54449
      • Marshfield Labs

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. The specimen is a nasopharyngeal swab collected using a cleared nasopharyngeal swab and transport medium.
2. The specimen is from an adult or pediatric, male or female subject who is either hospitalized, admitted to a hospital emergency department, visiting an outpatient clinica or resident of a long term care facility.
3. The specimen is from a patient for whom a requisition has been made for B. pertussis and/or B. parapertussis testing.
4. The specimen is from a patient exhibiting clinical signs and symptoms of respiratory tract infection consistent with B. pertussis or B. parapertussis.
5. The specimen was received in good condition (no leakage or drying of the specimen).
6. The specimen contains a minimum volume of 1000 μL.

Exclusion Criteria:

1. The specimen is not a nasopharyngeal swab collected using a cleared nasopharyngeal swab and transport medium.
2. The specimen was not properly collected, transported, processed or stored according to the instructions provided by the Sponsor in Section 10 below.
3. The specimen volume is <1000 μL.
4. Any specimen that was not tested per the complete testing algorithm provided by the Sponsor.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Blinded, Prospective Arm (1); Clinical performance of the ARIES Bordetella Assay for the detection of B. pertussis and B. parapertussis will be evaluated in prospectively collected, de-identified, left-over, clinical specimens.	Device: ARIES Bordetella Assay
Experimental: Blinded, Pre-selected Arm (2); In the event that an insufficient number of positive specimens are acquired for B. pertussis / B. parapertussis in Arm 1, clinical performance of the ARIES Bordetella Assay will be tested using banked, pre-selected, positive clinical specimens.	Device: ARIES Bordetella Assay
Experimental: Blinded, Contrived Arm (3); Contrived specimens will be tested using the ARIES Bordetella Assay to evaluate detection of B. parapertussis in the event that an insufficient number of positive specimens are acquired in Arm 2.	Device: ARIES Bordetella Assay

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Specificity and sensitivity of the ARIES Bordetella Assay in patients suspected of having respiratory infection attributable to B. pertussis or B. parapertussis.	Estimates of positive percent agreement and negative percent agreement for each target will be calculated based on a two-by-two table (reference method result vs. result from ARIES Bordetella Assay) for each target. In addition, 95% two sided confidence intervals will be provided. Positive agreement and negative agreement values will be provided for the entire prospective data set.	5 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical performance of the ARIES Bordetella Assay per clinical site.	Positive agreement and negative agreement values will be provided for each clinical site.	5 months
Clinical performance of the ARIES Bordetella Assay per age group.	Positive agreement and negative agreement values will be provided for pediatric vs. adult patients.	5 months
Clinical performance of the ARIES Bordetella Assay per patient sub-population.	Positive agreement and negative agreement values will be provided for each patient sub population (e.g., immuno-competent vs. immuno-compromised patients, and hospitalized vs. outpatient vs. long-term care facility).	5 months

Collaborators and Investigators

• Sponsor: Luminex Molecular Diagnostics
• Investigators: Study Director: Ronald Dunn, Luminex Molecular Diagnostics; Principal Investigator: Timothy S Uphoff, PhD, Marshfield Labs; Principal Investigator: Stephen Young, PhD, Tricore Reference Lab; Principal Investigator: Ryan Relich, PhD, IU Health Pathology Laboratory; Principal Investigator: Ted E Schutzbank, PhD, St. John Hospital & Medical Center; Principal Investigator: Amy L Leber, PhD, Nationwide Children's Hospital Laboratory

Publications and helpful links

General Publications

• Relich RF, Leber A, Young S, Schutzbank T, Dunn R, Farhang J, Uphoff TS. Multicenter Clinical Evaluation of the Automated Aries Bordetella Assay. J Clin Microbiol. 2019 Jan 30;57(2):e01471-18. doi: 10.1128/JCM.01471-18. Print 2019 Feb.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2016
• Primary Completion (Actual): November 1, 2016
• Study Completion (Actual): November 14, 2016

Study Registration Dates

• First Submitted: July 12, 2016
• First Submitted That Met QC Criteria: August 5, 2016
• First Posted (Estimate): August 11, 2016

Study Record Updates

• Last Update Posted (Actual): October 4, 2018
• Last Update Submitted That Met QC Criteria: October 2, 2018
• Last Verified: October 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Infections; Respiratory Tract Diseases; Disease Attributes; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Communicable Diseases; Whooping Cough; Bordetella Infections
• Other Study ID Numbers: LMA-BRD-01-CS-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No